Type 2 diabetes mellitus. Type 2 diabetes mellitus
Conditions
Interventions
Intervention 1: Intervention group: patients with type 2 diabetes, for 12 weeks, in addition to the standard diet, which includes 53% carbohydrates, 17% protein, and 30% fat, a nutritional consultant
Sponsors
Rasht University of Medical Sciences
Eligibility
Sex/Gender
All
Age
20 Years to 70 Years
Inclusion criteria
Inclusion criteria: Patients with an age range of 20 to 70 years Patients diagnosed with type 2 diabetes under drug therapy Serum glucose greater than 110 mg/dL Hemoglobin A1C maximum 9% Body mass index in the range of 25-30 Not using vitamin and mineral supplements, antioxidants, fiber supplements, omega-3 No history of kidney disease, kidney stones, digestive diseases, gallstones, and autoimmune diseases No current consumption of alcohol Not taking insulin
Exclusion criteria
Exclusion criteria: Change in the patient's disease treatment plan during the study Changing the type of drugs used, effective factors studied Reluctance to continue the study or cause any dissatisfaction regarding the taste of the oil or participation in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum lipid profile levels (triglycerides, total cholesterol, LDL-C and HDL-C). Timepoint: At the beginning of the study and 12 weeks later. Method of measurement: BT2000 device.;Fasting blood sugar. Timepoint: At the beginning of the study and 12 weeks later. Method of measurement: BT2000 device.;Serum insulin. Timepoint: At the beginning of the study and 12 weeks later. Method of measurement: BT2000 device.;Glycosylated hemoglobin. Timepoint: At the beginning of the study and 12 weeks later. Method of measurement: ELISA device.;Erythrocyte sedimentation rate. Timepoint: At the beginning of the study and 12 weeks later. Method of measurement: ELISA device.;Prothrombin Time. Timepoint: At the beginning of the study and 12 weeks later. Method of measurement: ELISA device.;Partial Thromboplastin Time. Timepoint: At the beginning of the study and 12 weeks later. Method of measurement: ELISA device.;Adropin. Timepoint: At the beginning of the study and 12 weeks later. Method of measurement: ELISA device.;Omentin-1. Timepoint: At the beginning of the study and 12 weeks later. Method of measurement: ELISA device.;Glutathione peroxidase activity. Timepoint: At the beginning of the study and 12 weeks later. Method of measurement: ELISA device.;Glutathione reductase activity. Timepoint: At the beginning of the study and 12 weeks later. Method of measurement: ELISA device.;Superoxide dismutase activity. Timepoint: At the beginning of the study and 12 weeks later. Method of measurement: ELISA device.;Catalase activity. Timepoint: At the beginning of the study and 12 weeks later. Method of measurement: ELISA device.;Paraoxonase activity. Timepoint: At the beginning of the study and 12 weeks later. Method of measurement: ELISA device.;Vitamin E. Timepoint: At the beginning of the study and 12 weeks later. Method of measurement: ELISA device.;Xanthine oxidase activity. Timepoint: At the beginning of the study and 12 weeks later. Method of measurement: ELISA device.;HS - C-reactiv | — |
Secondary
| Measure | Time frame |
|---|---|
| Mean systolic and diastolic blood pressure. Timepoint: At the beginning of the study and 12 weeks later. Method of measurement: Pressure indicator.;Body mass index. Timepoint: At the beginning of the study and 12 weeks later. Method of measurement: Centimeter and scales. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactZahra ahmadnia
Rasht University of Medical Sciences
Outcome results
None listed